BORIN, MICHAEL L.



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF MAILING	
I hereby certify under 37 C.F.R. 1.8(a) that this correspondence is being deposited with the United States Postal Service with	
ufficient postage as EXPRESS MAIL #EV 238066829 US on the date indicated below and in an envelope addressed to: Commission	ner
or Patents, P.O. Box 1450, Alexandria, VA 22313-1450.	
X]If checked, two copies of this correspondence are enclosed.	
/ 20 000 / Signature	
Pate of Deposit: Alan F. Feeney	
Printed name of person mailing correspondence	
Applicant: IGNATIOUS, Francis X. Art Unit: 1631	

3<sup>rd</sup> SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

ENCAPSULATION OF A WATER SOLUBLE PEPTIDE

Examiner:

AND AUTHORIZATION TO CHARGE DEPOSIT ACCOUNT Commissioner for Patents

a Petition under 37 CFR 1.97(d)(2), and

09/744,350

May 22, 2001

Serial No.:

Filed:

Title:

[ ]

P.O. Bo Alexand Sir:	x 1450 Iria, VA 22313-1450		
This Inf	formation Disclosure Statement is submitted:		
[]	under 37 CFR 1.129(a), or		
	(First/Second submission after Final Rejection)		
[ ]	under 37 CFR 1.97(b), or (Whichever occurs last of the following: within three months of filing national application; within three months of date of entry of the national stage in international application; before the mailing date of first office action on the merits; or before the mailing of a first Office action after the filing of a request for continued examination		
[X]	under 37 CFR 1.97(c) together with either:		
	[ ] a Statement under 37 CFR 1.97(e), as checked below, or		
	[X] a \$180.00 fee under 37 CFR 1.17(p), or		
	(After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)		
[]	under 37 CFR 1.97(d) together with:		
	[ ] a Statement under 37 CFR 1 97(e) as checked below, and		

	[ ] a \$130.00 petition fee set forth in 37 CFR 1.17(i).			
	(Filed after final action or notice of allowance, whichever occurs first, but before payment of the issue fee)			
[ ]	Applicant requests that the attached IDS and cited reference(s) [ (Filed after payment of issue fee)	] be placed in the application filewrapper.		

[ X] Some of the listed references were cited in a European Search Report in a counterpart European application or cited in a communication from a foreign patent office in a counterpart foreign application.

[X]	Enclosed herewith is form PTO/SB/08B (2 pages), with a copy of each reference noted thereon.			
[]	Copies of the reference(s) noted on the enclosed form PTO/SB/08 were previously cited by or submitted to the Patent and Trademark Office in connection with U.S. Application Serial No. [ ], from which the present application claims benefit under 35 U.S.C. § 120 (37 C.F.R. 1.98(d)).			
Concise	e Explanation Requirement (non-English references):			
[]	The "concise explanation" requirement for reference(s) under 37 CFR 1.98(a)(3) is satisfied by:			
	[ ] the explanation provided on the attached sheet.			
	[ ] the explanation provided in the Specification.			
	[ ] submission of the enclosed International Search Report.			
	[ ] the enclosed English language abstracts.			
enclose	quested that the information disclosed herein be made of record in this application, and that the references listed on the d form PTO/SB/08B appear under the "References Cited" heading of any Patent which issues from this application, 1302.12).			
Stateme	ent Under 37 CFR 1.97(e):			
[ ]	Each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or			
[ ]	No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.			
Method	of payment:			
[]	A check for the fee noted above is enclosed, or the fee has been included in the check with the accompanying Reply.			
[X]	No fee is believed to be due for this submission, however, Applicant(s) hereby authorize the Commissioner to charge any fees that may be deemed to be due or to credit any overpayment to Deposit Account No. 50-0590. Two copies of this Statement are enclosed.			
[]	The Commissioner is hereby authorized to charge any deficiency in fees and credit any overpayment to Deposit Account 50-0590. Two copies of this Statement are enclosed.			
	Respectfully submitted,			
Dated:	BIOMEASURE, INCORPORATED  By Alan F. Feeney, Attorney for Applicant(s)  Registration No.: 43,609			
	asure, Incorporated  ole Street			

Biomeasure, Incorporated 27 Maple Street Milford, Massachusetts 01757 Phone: (508)478-0144 Facsimile: (508) 473-3531 JAN 3 0 2004 &

DOC	ΙD	NO.

PTO-1449 REPRODUCED

ATTORNEY DOCKET NO. 00537-181002

APPLICATION NO. 09/744,350

## INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

APPLICANT IGNATIOUS, Francis X.

FILING DATE 05/22/2001

EXAMINER/ART UNIT BORIN, M. / 1631

## U.S. PATENT DOCUMENTS EXAM-SUB-FILING DATE INER DOCUMENT NUMBER DATE CLASS NAME CLASS ΙF INI-APPROPRIATE TIAL DB DC DΕ DF DG DH DI DЈ DK FOREIGN PATENT DOCUMENTS SUB-TRANSLATION DOCUMENT NUMBER DATE COUNTRY CLASS CLASS YES DLWO 97/39738 10/30/1997 PCT WO 93/24150 12/09/1993 PCT DN DO DP DQ OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

HERMANN, J., et al. "Biodegradable, Somatostatin Acetate Containing Microspheres Prepared by Various Aqueous and Non-aqueous Solvent Evaporation Methods," European Journal of Pharmaceutics and Biopharmaceutics 45(1998):75-82.

EXAMINER

DATE CONSIDERED